Logo do repositório

Percorrer por autor "Kuliešė, Monika"

A mostrar 1 - 2 de 2
  • Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
    Publication . Rose, Angela M.C.; Nicolay, Nathalie; Sandonis Martín, Virginia; Mazagatos, Clara; Petrović, Goranka; Niessen, F Annabel; Machado, Ausenda; Launay, Odile; Denayer, Sarah; Seyler, Lucie; Baruch, Joaquin; Burgui, Cristina; Loghin, Isabela I.; Domegan, Lisa; Vaikutytė, Roberta; Husa, Petr; Panagiotakopoulos, George; Aouali, Nassera; Dürrwald, Ralf; Howard, Jennifer; Pozo, Francisco; Sastre-Palou, Bartolomé; Nonković, Diana; Knol, Mirjam J.; Kislaya, Irina; Luong Nguyen, Liem binh; Bossuyt, Nathalie; Demuyser, Thomas; Džiugytė, Aušra; Martínez-Baz, Iván; Popescu, Corneliu; Duffy, Róisín; Kuliešė, Monika; Součková, Lenka; Michelaki, Stella; Simon, Marc; Reiche, Janine; Otero-Barrós, María Teresa; Lovrić Makarić, Zvjezdana; Bruijning-Verhagen, Patricia C.J.L.; Gómez, Verónica; Lesieur, Zineb; Barbezange, Cyril; Van Nedervelde, Els; Borg, Maria-Louise; Castilla, Jesús; Lazar, Mihaela; O’Donnell, Joan; Jonikaitė, Indrė; Demlová, Regina; Amerali, Marina; Wirtz, Gil; Tolksdorf, Kristin; Valenciano, Marta; Bacci, Sabrina; Kissling, Esther; I-MOVE-COVID-19 Hospital Study Team; VEBIS Hospital Study Team
    Introduction: Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)-dominant periods, 2021. Methods: Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. Results: We included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90–179 days before onset. Conclusions: Our results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.
    2023-11Artigo científico Acesso aberto Ver mais
  • Vaccine effectiveness against influenza A in older adults and the effect of chronic conditions: results from the I-MOVE and VEBIS multicentre European hospital case-control studies, 2015/16-2023/24
    Publication . Rose, Angela Mary Catherine; Nicolay, Nathalie; Mazagatos, Clara; Martínez-Baz, Iván; Launay, Odile; De Mot, Laurane; Bella, Antonino; Lazar, Mihaela; Machado, Ausenda; Kuliešė, Monika; Abela, Stephen; Vučina, Vesna Višekruna; van Gageldonk-Lafeber, Rianne; Bino, Silvia; Dürrwald, Ralf; Paradowska-Stankiewicz, Iwona; Horváth, Judit Krisztina; Duffy, Róisín; Husa, Petr; McMenamin, Jim; Pozo, Francisco; Howard, Jennifer; Latorre-Millán, Miriam; Castilla, Jesús; Nguyen, Liem Binh Luong; Dauby, Nicolas; Riccardo, Flavia; Ivanciuc, Alina; Gomez, Verónica; Jančorienė, Ligita; Xuereb, Gerd; Petrović, Goranka; Marbus, Sierk; Vasili, Adela; Tolksdorf, Kristin; Bogusz, Joanna; Oroszi, Beatrix; Domegan, Lisa; Součková, Lenka; Marsh, Kimberley; Bacci, Sabrina; Kissling, Esther; I-MOVE & VEBIS Hospital Network teams
    Background: The Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE/I-MOVE+) and Vaccine Effectiveness, Burden and Impact Studies (VEBIS) hospital networks have conducted seasonal multicentre, test-negative, case-control studies in Europe to measure influenza vaccine effectiveness (IVE) since 2015/16. We measured the effect of chronic conditions on VE of influenza A subtypes among older adults (≥ 65 years) using pooled-season data (2015/16-2023/24). Methods: Hospital teams swabbed patients with severe acute respiratory infection (SARI) within 7 days of symptom onset. Cases were RT-PCR positive for influenza A(H1N1)pdm09 or A(H3N2); controls negative for any influenza virus. We calculated overall pooled-season IVE against influenza A(H1N1)pdm09 and A(H3N2), adjusted for study site, sex, age and onset date; and stratified by number of and by each chronic condition (diabetes, heart disease, lung disease/asthma, immunosuppression, kidney disease, liver disease, cancer, obesity). We investigated interaction between vaccination and each condition. Results: We included 1805 A(H1N1)pdm09 cases with 16,329 controls; 2590 A(H3N2) cases with 14,920 controls, from 13 study sites (12 countries). Over all seasons, 63-67% cases and 70% controls had ≥ 2 chronic conditions. Against A(H1N1)pdm09, pooled-season IVE was 37% (95%CI: 29-44) overall; 49% (95%CI: 9-72), 30% (95%CI: 12-44) and 38% (95%CI: 29-46) in those with 0, 1, ≥ 2 chronic conditions. Most IVE point estimates were 34-45%, apart from immunosuppression (-7%), kidney disease (17%) and liver disease (54%), but 95% CIs overlapped. Significant interaction was observed for kidney disease (p = 0.02) and immunosuppression (p = 0.01). Against A(H3N2), pooled-season IVE was 17% (95%CI: 8-25) overall; 15% (95%CI: -26-42), 11% (95%CI: -8-27) and 18% (95%CI: 7-28) in those with 0, 1, ≥ 2 chronic conditions. Here, IVE point estimates ranged 13-25%, apart from immunosuppression (5%), kidney disease (6%) and liver disease (31%), although 95% CIs overlapped. There were no significant interactions. Conclusions: Pooled-season results suggest low-moderate VE against influenza A subtypes among older SARI patients; higher against A(H1N1)pdm09 than A(H3N2), with little evidence of chronic condition modifying effect, apart from kidney disease and immunosuppression. We stress the importance of developing improved influenza vaccines for specific populations, and encourage further research into the effect of chronic conditions on IVE in older adults.
    2025-11-03Artigo científico Acesso aberto Ver mais